Image source: Canva Around 20,000 Americans are affected by acute myeloid leukemia (AML) each year. AML is a type of cancer that originates in the bone marrow and rapidly enters the bloodstream. Additionally, many individuals are impacted by myelodysplastic syndromes (MDS), which are blood disorders that result in the improper formation or functioning of blood … Continue reading CIRM awards $8 million to Support Groundbreaking Gene Therapy for AML and MDS
AML
CIRM-supported therapy for blood cancers gets FDA fast track
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST People often complain about how long it can take to turn a scientific discovery into an approved therapy for patients. And they’re right. It can take years, decades even. But for Immune-Onc Therapeutics the path to FDA approval may just have been shortened. Back in April … Continue reading CIRM-supported therapy for blood cancers gets FDA fast track
CIRM Board Approves Clinical Trials for Blood Cancer and Pediatric Brain Tumors
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $14.4 million for two new clinical trials for blood cancer and pediatric brain tumors. These awards bring the total number of CIRM-funded clinical trials to 70. $6.0 million was awarded to Immune-Onc Therapeutics to conduct a clinical trial for patients with acute … Continue reading CIRM Board Approves Clinical Trials for Blood Cancer and Pediatric Brain Tumors
CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Mark Chao, M.D., Ph.D., cofounder of Forty Seven, Inc. and current VP of oncology clinical research at Gilead Sciences An antibody therapeutic, magrolimab, being tested for myelodysplastic syndrome (MDS), a group of cancers in which the bone marrow does not produce enough healthy blood cells , was granted breakthrough therapy designation with the Food and Drug Administration … Continue reading CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Therapy developed with CIRM award used in new clinical trial for COVID-19
Dr. Joshua Rhein, Assistant Professor of Medicine in the University of Minnesota Medical School's Division of Infectious Diseases and International Medicine Image Credit: University of Minnesota While doctors are still trying to better understand how to treat some of the most severe cases of COVID-19, researchers are looking at their current scientific "toolkit" to see if … Continue reading Therapy developed with CIRM award used in new clinical trial for COVID-19
CIRM funded clinical trial shows promising results for patients with blood cancers
An illustration of a macrophage, a vital part of the immune system, engulfing and destroying a cancer cell. Antibody 5F9 blocks a "don't eat me" signal emitted from cancer cells. Courtesy of Forty Seven, Inc. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both types of blood cancers that can be difficult to treat. CIRM … Continue reading CIRM funded clinical trial shows promising results for patients with blood cancers
CIRM-supported study shows promise in fighting acute myeloid leukemia
For years chemotherapy has been a mainstay in the war against cancer. While it can be very effective it can also come with some nasty side effects. Since chemo works by killing rapidly growing cells, it not only hits the cancer cells, but can also hit other rapidly growing cells too, including those in our … Continue reading CIRM-supported study shows promise in fighting acute myeloid leukemia
The Stem Cellar 